IO Biotech, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address OLE MAALOES VEH 3, COPENHAGEN, G7, 2200
Mailing Address OLE MAALOES VEH 3, COPENHAGEN, G7, 2200
Phone 4570702980
Fiscal Year End 1231
EIN 870909276
Financial Overview
FY2024
-$86.08M
Net Income
$150.72M
Total Assets
$20.68M
Total Liabilities
$138.85M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 6, 2026 | View on SEC |
| 8-K Current report of material events | January 30, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | January 23, 2026 | View on SEC |
| 8-K Current report of material events | January 21, 2026 | View on SEC |
| 8-K Current report of material events | December 19, 2025 | View on SEC |
| 8-K Current report of material events | November 21, 2025 | View on SEC |
| 8-K Current report of material events | November 18, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 14, 2025 | View on SEC |
Material Events
8-K Financial Distress February 13, 2026
High Impact
- Positive top-line results from Phase 2 clinical trial for IO-102 in advanced melanoma, showing 29% objective response rate (ORR) and 6.9 months median progression-free survival (PFS).
- IO-102 combined with Keytruda could offer a meaningful improvement for advanced melanoma patients.
8-K Financial Distress January 30, 2026
High Impact
- Company is actively exploring strategic alternatives (merger, acquisition, asset sale, financing) to secure future development.
- Implementing significant cost-cutting measures to extend financial runway and buy time for a solution.
8-K Strategy Change January 21, 2026
High Impact
- IO Biotech is exploring significant strategic alternatives, including merger, acquisition, partnerships, asset sales, or new financing options.
- This process could lead to a strong acquisition offer or other financially beneficial transactions, potentially maximizing shareholder value.
8-K Financial Distress December 19, 2025
High Impact
- IO Biotech, Inc. received a warning from Nasdaq for its stock trading below $1.00 per share for 30 consecutive trading days, violating Nasdaq's listing rules.
- The company now faces the risk of delisting from the Nasdaq stock exchange if it cannot regain compliance.
Related Companies
Companies in the same industry (SIC: 2834)
Werewolf Therapeutics, Inc.
HOWL Pharmaceutical Preparations
Zenas BioPharma, Inc.
ZBIO Pharmaceutical Preparations
Centessa Pharmaceuticals plc
CNTA Pharmaceutical Preparations
Karyopharm Therapeutics Inc.
KPTI Pharmaceutical Preparations
VERTEX PHARMACEUTICALS INC / MA
VRTX Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.